Diary - News
All news 1 PRESS RELEASE PRESS RELEASE ERYTECH announces enrollment of first patient in Phase II study of ERY-ASP in pancreatic cancer
ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces the enrollment of the first patient in its Phase II study with ERY-ASP in second line treatment of patients affected by pancreatic cancer.
Three months after its authorization by the ANSM, the French authority for drug safety, a first patient has been enrolled.
